z-logo
open-access-imgOpen Access
Effects of Antiproteinuric Intervention on Elevated Connective Tissue Growth Factor (CTGF/CCN-2) Plasma and Urine Levels in Nondiabetic Nephropathy
Author(s) -
Maartje C. J. Slagman,
Tri Q. Nguyen,
Femke Waanders,
Liffert Vogt,
Marc H Hemmelder,
Gozewijn D. Laverman,
Roel Goldschmeding,
Gerarda Navis
Publication year - 2011
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.08190910
Subject(s) - ctgf , medicine , endocrinology , losartan , kidney disease , proteinuria , nephropathy , fibrosis , kidney , urology , angiotensin ii , growth factor , blood pressure , diabetes mellitus , receptor
Connective tissue growth factor (CTGF/CCN-2) is a key player in fibrosis. Plasma CTGF levels predict end-stage renal disease and mortality in diabetic chronic kidney disease (CKD), supporting roles in intra- and extrarenal fibrosis. Few data are available on CTGF in nondiabetic CKD. We investigated CTGF levels and effects of antiproteinuric interventions in nondiabetic proteinuric CKD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here